langue originale | Anglais |
---|---|
Pages (de - à) | iv192-iv237 |
journal | Annals of Oncology |
Volume | 29 |
Les DOIs | |
état | Publié - 1 oct. 2018 |
Modification externe | Oui |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Annals of Oncology, Vol 29, 01.10.2018, p. iv192-iv237.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - Metastatic non-small cell lung cancer
T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
AU - Planchard, D.
AU - Popat, S.
AU - Kerr, K.
AU - Novello, S.
AU - Smit, E. F.
AU - Faivre-Finn, C.
AU - Mok, T. S.
AU - Reck, M.
AU - Van Schil, P. E.
AU - Hellmann, M. D.
AU - Peters, S.
N1 - Funding Information: DP has reported honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; consulting, advisory role or lectures for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche and has received travel grants from AstraZeneca, Roche, Novartis, prIME Oncology and Pfizer; SPo has reported honoraria from Pfizer, Boehringer Ingelheim, AstraZeneca, Roche, Lilly, Novartis, Takeda, Guardant Health, Bristol-Myers Squibb and consulting/advisory role for Boehinger Ingleheim, Roche, Lilly, Novartis, Pfizer and research funding from Boehringer Ingelheim, Epizyme, Bristol-Myers Squibb, Clovis Oncology, Roche, Lilly, Takeda; KMK has reported lecture fees and consultancy for AstraZeneca, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharpe & Dohme, Merck Serono, Novartis, Pfizer, Roche, Roche Diagnostics; SN has reported membership of the speaker bureau of Eli Lilly, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Boehringer Ingelheim, Roche, Incyte, Takeda; CFF has reported research/travel funding from AstraZeneca and Merck Sharpe & Dohme; TM has reported holding stock in Sanomics Ltd. and Hutchison Chi-Med, conducting research sponsored by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis oncology, Merck Sharp and Dohme, Novartis, Pfizer, Roche, SFJ Pharmaceuticals and XCovery; has received speaker's fee from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Sharp and Dohme, Novartis, BMS, Taiho, Takeda Oncology, prIME Oncology and Amoy Diagnostics Co, LTD and honoraria from AstraZeneca, Boehringer Ingelheim, Roche/Genentech, Pfizer, Eli Lilly, Merck Sorono, Merck Sharp and Dohme, Novartis, SFJ Pharmaceuticals, ACEA Biosciences Inc, Vertex Pharmaceuticals, Bristol-Myers Squibb, OncoGenex Technologies Inc, Celgene, Ignyta Inc, Cirina, Fishawack Facilitate Ltd, Janssen, Takeda, Hutchison Chi-Med, OrigiMed, Henfrui Therapeutics Inc, Sanofi-Aventis R&D and Yuhan Corporation for attending advisory boards; MH has reported honoraria for consultancy for Roche/Genentech, AstraZeneca, Merck, Bristol–Myers Squibb, Janssen, Mirati, Syndax, Shattuck Labs and has received research funding from Bristol-Myers Squibb; MR has reported honoraria for lectures and consultancy from AstraZeneca, Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Novartis, Abbvie, Pfizer, Merck Sharpe & Dohme, Merck, Roche, Lilly; SPe has reported educational grants, consultation, advisory boards and/or lectures for Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Novartis, Merck Serono, Pfizer, Regeneron and Takeda; PEVS has reported no conflicts of interest. ES has not reported any potential conflicts of interest.
PY - 2018/10/1
Y1 - 2018/10/1
UR - http://www.scopus.com/inward/record.url?scp=85054351450&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy275
DO - 10.1093/annonc/mdy275
M3 - Article
C2 - 30285222
AN - SCOPUS:85054351450
SN - 0923-7534
VL - 29
SP - iv192-iv237
JO - Annals of Oncology
JF - Annals of Oncology
ER -